Yahoo CEO Marissa Mayer recently announced her plan to make acquisitions to revitalize and grow Yahoo. Her announcement generated a lot of reaction, but not so much about her ability to execute M&As — Mayer brings M&A experience gained at Google, and if she sticks with relatively small, educational acquisitions, failure on one deal will not break the company.… Read more
Permanent link to this article: http://blog.insead.edu/2012/10/yahoos-challenge-finding-a-viable-growth-path-via-acquisitions/
By Laurence Capron & Will Mitchell
Cipla, an India-based producer of low cost antiretroviral drugs (ARVs) is one of the biggest success stories in the pharma industry. Most of its sales are in the developing world (including 40% in Africa) — where it sells its HIV drugs for about $350 per year per patient — yet it is as profitable as the pharma giants of Europe, North America, and Japan.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/the-company-outsmarting-big-pharma-in-africa/
By Laurence Capron and Will Mitchell
Historically, big pharma firms made their own drugs. They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/big-pharmas-mixed-modes-of-growth/
In business, longevity has merit. Research shows that about a third or more of start ups discontinue within the first three years. Even for those that survive, most remain small, and unable to grow beyond their initial niche. Surviving for a long time requires dealing with ownership and management transitions, new technologies, new market trends, and new competitors.… Read more
Permanent link to this article: http://blog.insead.edu/2012/05/where-are-europes-gazelles/
